1 completed, 1 not yet recruiting, 1 terminated. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Eye Manifestations: new trials by email Literature Review of Eye Manifestations trials Research Report on Eye Manifestations
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP). Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution - Neuropathic Corneal Pain | Phase 3 | Not yet recruiting | Okyo Pharma Ltd | 111 | 2026-09-01 | 2026-09-29 |
| Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE). - Corneal Endothelial Cell Loss, Mydriasis | Phase 3 | Completed | Cairo University | 30 | 2019-02-01 | 2020-05-20 |
| Endothelial Cell Loss After Cataract Surgery Standard phacoemulsification, Reduced ultrasound phacoemulsification - Cataracts | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 39 | 2009-07-01 | 2014-08-25 |
Cataract (2) · Corneal Endothelial Cell Loss (2) · Eye Pain (1) · Mydriasis (1)
Eye Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Corneal Diseases (2) · Lens Diseases (2) · Pathologic Processes (2) · Postoperative Complications (2) · Neurologic Manifestations (1) · Pain (1) · Pupil Disorders (1)
Cairo University (1) · Okyo Pharma Ltd (1) · University of California, San Francisco (1)
United States (2) · Egypt (1)
David Hwang, MD (1) · Flavio Mantelli, MD, PhD (1)